LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

Search

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

32.27 4.47

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

30.89

Max

34.17

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-14M

-81M

Pardavimai

75K

75K

Pelnas, tenkantis vienai akcijai

-1.22

Pelno marža

-108,422.667

Darbuotojai

198

EBITDA

-7.8M

-81M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+74.47% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

394M

2B

Ankstesnė atidarymo kaina

27.8

Ankstesnė uždarymo kaina

32.27

Naujienos nuotaikos

By Acuity

50%

50%

147 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-22 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-22 23:50; UTC

Rinkos pokalbiai

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-22 23:41; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

2026-03-22 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

2026-03-22 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Participated in Aurum Resources Equity Raising

2026-03-22 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

2026-03-22 22:22; UTC

Rinkos pokalbiai
Svarbiausios naujienos

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

2026-03-22 21:25; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

2026-03-22 21:22; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

2026-03-22 21:21; UTC

Rinkos pokalbiai

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

74.47% į viršų

12 mėnesių prognozė

Vidutinis 53.91 USD  74.47%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

10

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

147 / 350 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat